|Articles|February 1, 2000

February 2000
Volume 6
Issue 2

Is Cost-Effectiveness Modeling Useful?

Author(s)Paul C. Langley, PhD

Download PDF: Is Cost-Effectiveness Modeling Useful?

Articles in this issue

over 26 years ago

Article

Barriers to Using Cost-Effectiveness Analysis in Managed Cae Decision Making

over 26 years ago

Article

Asking Women to See Nurses or Unfamiliar Physicians as Part of Primary Care Redesign

over 26 years ago

Article

Cost of Treating Influenza in Emergency Department and Hospital Settings

over 26 years ago

Article

Hospital Resource Consumption in Patients with Diabetes and Multivessel Coronary Disease Undergoing Revascularization

over 26 years ago

Article

Ischemic Stroke: Acute Management and Secondary Prevention

over 26 years ago

Article

Cost-Effectiveness Analysis under Managed Care: Not Yet Ready for Prime Time?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Is Cost-Effectiveness Modeling Useful?

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes

Childhood Influenza Vaccine Rates Decreased From 2017 to 2023

What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO